Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.34 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711938 | 0.90 | CCNA2 (0.34) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL13294275 | 0.81 | CCNA2 (0.34) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL19168711 | 0.81 | CCNA2 (0.34) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL9176156 | 0.80 | CCNA2 (0.44) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL14327638 | 0.80 | EPHX2 (0.37) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL8188002 | 0.79 | CCNA2 (0.38) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL29102259 | 0.79 | MEN1 (0.38) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL17520611 | 0.78 | TAS1R3 (0.46) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL7986917 | 0.77 | CCNA2 (0.37) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL1618268 | 0.77 | CCNA2 (0.37) | CCNA2CDK2CCNA1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724825-A | Mer/HDAC double-target inhibitor and application thereof in preparation of antitumor drugs | 河北科技大学 | 2024-10-01 | — | — | CN | claimed |
| CN-122036688-A | Solid form of hydroxyamide compound and preparation method and application thereof | 四川汇宇制药股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12172965-B2 | Drug conjugate comprising quinoline derivatives | Universite Paris-Saclay (FR) | 2024-12-24 | — | — | US | disclosed |
| CN-119173510-A | Hydroxy amide derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118724825-A | Mer/HDAC double-target inhibitor and application thereof in preparation of antitumor drugs | 河北科技大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117551032-A | Drug conjugates comprising quinoline derivatives | 国家科学研究中心 | 2024-02-13 | — | — | CN | disclosed |
| CN-112955434-B | Drug conjugates comprising quinoline derivatives | 国家科学研究中心 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023222115-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | 四川汇宇制药股份有限公司 | 2023-11-23 | — | — | WO | disclosed |
| CN-112955434-A | Drug conjugates comprising quinoline derivatives | 国家科学研究中心 | 2021-06-11 | — | — | CN | disclosed |
| WO-2020058290-A1 | DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020058290-A1 | DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-03-26 | — | — | WO | disclosed |
| US-8980877-B2 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.R.L. (IT) | 2015-03-17 | — | — | US | disclosed |
| EP-2488529-B1 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC SRL (IT) | 2014-08-20 | — | — | EP | disclosed |
| US-20120258949-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.r.I. (IT) | 2012-10-11 | — | — | US | disclosed |
| EP-2488529-A2 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.r.l. (IT) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045265-A2 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2011-04-21 | — | — | WO | disclosed |
| EP-2311840-A1 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.r.l. (IT) | 2011-04-20 | — | — | EP | disclosed |
| EP-2279187-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.r.l. (IT) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258949-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC4, HDAC1 | CCNA2 749/4885CDK2 338/4885CCNA1 495/4885 |
| US-12172965-B2 | Drug conjugate comprising quinoline derivatives | HRH3, ABCC3, ORC3 | CCNA2 1014/4885CDK2 1208/4885CCNA1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.